UCB S.A. UNSP.ADR 1/2(UNC0)

Description: UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

---

Keywords: Biopharmaceutical Autoimmune Disease Alzheimer's Disease Monoclonal Antibodies Parkinson's Disease Rheumatoid Arthritis Arthritis Psoriasis Osteoporosis Epilepsy Crohn's Disease Rheumatology Allergies Systemic Lupus Erythematosus Psoriatic Arthritis Plaque Psoriasis Myasthenia Gravis Ankylosing Spondylitis Treatment Of Osteoporosis Ucb Immunology Diseases Restless Legs Syndrome Vimpat Certolizumab Pegol Cimzia Keppra Neupro Alprazolam Contract Manufacturing Activities Dravet Syndrome Inflammatory Tnf Mediated Diseases Xyzal Zyrtec Axial Spondyloarthritis Cdkl5 Deficiency Disorder Epilepsy Seizure Stereotypical Prolonged Seizures Treatment For Epilepsy Atropic Dermatitis Bimekizumab Spondyloarthritis Tk2 Deficiency Disorder

---

Home Page: www.ucb.com

AllEe de la Recherche, 60
Brussels, 1070
Belgium
Phone: 32 2 559 99 99

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)